Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic treatments primarily within the United States. Their leading experimental drug, edasalonexent, is an oral small molecule undergoing Phase III clinical trials for Duchenne Muscular Dystrophy (DMD), functioning by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells. Additionally, the company is developing CAT-5571 as a potential treatment for cystic fibrosis. Catabasis also engages in collaborative research, including a preclinical partnership with the Jain Foundation to investigate edasalonexent for dysferlinopathy, and an agreement with the Bill & Melinda Gates Medical Research Institute to study CAT-5571 for both drug-sensitive and drug-resistant tuberculosis. The company was established in 2008 and is based in Boston, Massachusetts.